Senseonics, a medical technology company focused on implantable Continuous Glucose Monitoring (CGM) Systems for people with diabetes, has partnered with Welldoc, a leader in AI-powered health solutions, to develop a new custom mobile application for Eversense 365. The strategic partnership aims to leverage Welldoc's expertise in AI to enhance the functionality and user experience of the Eversense 365 system. This collaboration marks a significant step in integrating advanced digital health solutions into diabetes management.

Partnership Details

The agreement focuses on the co-development of a tailored mobile application specifically designed for the Eversense 365 CGM system. By combining Senseonics' implantable sensor technology with Welldoc's AI-powered platform, the companies intend to provide a more comprehensive and intuitive tool for patients. The application will feature personalized insights and data-driven recommendations to support diabetes care.

Strategic Objectives

The primary objective of this partnership is to improve the overall user experience for individuals relying on the Eversense 365 system. The integration of AI capabilities is expected to offer real-time analytics and actionable health data. This move aligns with the growing trend of digital therapeutics in chronic disease management.